Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA2D1 | P54289 | 3/20 | 0.53 |
| ▸ | CACNA1B | Q00975 | 3/20 | 0.53 |
| ▸ | CACNB1 | Q02641 | 3/20 | 0.53 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.51 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.51 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.51 |
| ▸ | DRD1 | P21728 | 3/20 | 0.51 |
| ▸ | DRD3 | P35462 | 3/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.51 |
| ▸ | HTR1A | P08908 | 2/20 | 0.51 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.51 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.51 |
| ▸ | BCL2 | P10415 | 1/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17428330 | 1.00 | CACNA2D1 (0.53) | CACNA2D1CACNA1BCACNB1CHRM2ADRA2A | |
| SCHEMBL3457922 | 0.87 | L3MBTL3 (0.61) | CHRM2ADRA2ACHRM1DRD1DRD3 | |
| SCHEMBL20697765 | 0.85 | CACNA2D1 (0.51) | CACNA2D1CACNA1BCACNB1CHRM2ADRA2A | |
| SCHEMBL19075516 | 0.85 | CACNA2D1 (0.51) | CACNA2D1CACNA1BCACNB1CHRM2ADRA2A | |
| SCHEMBL21075238 | 0.85 | CACNA2D1 (0.53) | CACNA2D1CACNA1BCACNB1CHRM2ADRA2A | |
| SCHEMBL23118426 | 0.84 | CACNA2D1 (0.50) | CACNA2D1CACNA1BCACNB1CHRM2ADRA2A | |
| SCHEMBL19075587 | 0.84 | CACNA2D1 (0.50) | CACNA2D1CACNA1BCACNB1CHRM2ADRA2A | |
| SCHEMBL23118427 | 0.84 | CACNA2D1 (0.50) | CACNA2D1CACNA1BCACNB1CHRM2ADRA2A | |
| SCHEMBL21075702 | 0.79 | CHRM2 (0.46) | CACNA2D1CACNA1BCACNB1CHRM2ADRA2A | |
| SCHEMBL1741576 | 0.78 | MEN1 (0.74) | CACNA2D1CACNA1BCACNB1SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3166939-B1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH INC (US) | 2019-06-05 | — | — | EP | disclosed |
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | RDX, C1R, MTX1 | CACNA2D1 4055/4885CACNA1B 1812/4885CACNB1 2837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.